Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 5/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3408684 | 0.92 | BDKRB1 (0.40) | BDKRB1HCRTR1HCRTR2LMNAMAPK1 | |
| SCHEMBL3407853 | 0.88 | HCRTR1 (0.37) | BDKRB1HCRTR1HCRTR2LMNAMAPK1 | |
| SCHEMBL3408516 | 0.86 | HCRTR1 (0.36) | HCRTR1HCRTR2LMNAFKBP1A | |
| SCHEMBL3406175 | 0.86 | BDKRB1 (0.41) | BDKRB1HCRTR1HCRTR2 | |
| SCHEMBL3408874 | 0.84 | HCRTR1 (0.38) | BDKRB1HCRTR1HCRTR2LMNAMAPK1 | |
| SCHEMBL3311493 | 0.83 | OPRM1 (0.45) | BDKRB1HCRTR1HCRTR2 | |
| SCHEMBL3407195 | 0.82 | HCRTR1 (0.39) | BDKRB1HCRTR1HCRTR2 | |
| SCHEMBL645171 | 0.80 | FKBP1A (0.37) | BDKRB1HCRTR1HCRTR2LMNAMAPK1 | |
| SCHEMBL3407386 | 0.80 | HCRTR1 (0.36) | BDKRB1HCRTR1HCRTR2FKBP1A | |
| SCHEMBL3405986 | 0.80 | MC4R (0.40) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257527-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-08 | — | — | EP | claimed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | claimed |
| WO-2009115257-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-09-24 | — | — | WO | claimed |
| EP-2257527-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-08 | — | — | EP | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| WO-2009115257-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253669-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | BDKRB1 3589/4885HCRTR1 4142/4885HCRTR2 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.